Creon and Pregnancy
Because no studies have been done in pregnant women or animals, Creon (pancrelipase) is considered a pregnancy Category C medication. This means that this drug may not be safe for use in women who are pregnant. However, in many cases, the benefits of using this drug in the mother are likely to outweigh the potential risks to the unborn child.
Creon® (pancrelipase) is a prescription medication used to treat pancreatic enzyme deficiencies. At this time, it is unclear if this drug is safe for use during pregnancy.
The U.S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Creon is classified as a pregnancy Category C medicine.
Pregnancy Category C is given to medicines that have not been studied in pregnant humans but do appear to cause harm to the fetus in animal studies. Also, medicines that have not been studied in any pregnant women or animals are automatically given a pregnancy Category C rating.
Creon was given a pregnancy Category C rating because it has not been formally studied in any pregnant humans or animals. The potential risks, which are largely unknown at this time, must be weighed against the risks of not treating a pancreatic enzyme deficiency in a pregnant woman. Not treating the deficiency could lead to malnutrition and poor weight gain in the mother, which are associated with problems for the fetus during pregnancy. In many cases, the benefits will outweigh the likely risks.
If you are pregnant or thinking of becoming pregnant while taking Creon, let your healthcare provider know. He or she will consider both the benefits and risks before making a recommendation in your particular situation.